Trehalose Phospholipid Compositions for Mincle Agonist Adjuvants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current research on Gram-negative bacterial lipid endotoxins focuses primarily on LPS-TLR4 interactions, leaving a need for the identification of other targets that contribute to the virulence of pathogens like Salmonella species, which can serve as better immunogens for vaccine design and diagnostics.
Innovation Solution
Discovery and development of trehalose phospholipids, specifically 6-phosphatidyltrehalose (PT) and 6,6′-diphosphatidyltrehalose (diPT), which stimulate immune responses through C-type lectin receptors like Mincle, and their use as adjuvants for vaccine development and diagnostic tools.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If research focuses on LPS-TLR4 interactions, then understanding of endotoxin mechanisms is improved, but identification of new immunogenic targets is limited
Solution Approach 1:
The patent extracts and isolates trehalose phospholipids from Gram-negative bacterial cell walls as a separate target class from LPS, enabling independent study and application of these lipids as vaccine immunogens without being confined to LPS-TLR4 research paradigms
Solution Approach 2:
The patent introduces a new dimensional approach by targeting C-type lectin receptors (a different receptor family than TLR4) with trehalose phospholipids, expanding the immunogenic target landscape from a single LPS-TLR4 axis to multiple parallel pathways
2Reliability
If conventional adjuvants are used in vaccines, then immune response is stimulated, but response strength and specificity are limited
Solution Approach 1:
The patent changes the chemical parameter of adjuvant structure by using trehalose phospholipids with specific fatty acid compositions and trehalose headgroups, which fundamentally alters the immune response profile compared to conventional adjuvants, achieving both strength and specificity
Solution Approach 2:
The patent creates composite vaccine formulations combining trehalose phospholipid adjuvants with specific antigens, where the synergistic interaction between the unique adjuvant structure and antigen produces enhanced and more specific immune responses than either component alone
3Measurement precision
If diagnostic methods target LPS, then detection of Gram-negative bacteria is achieved, but sensitivity and specificity for certain infections are insufficient
Solution Approach 1:
The patent applies local quality detection by targeting specific trehalose phospholipid structures (with particular fatty acid compositions) that are locally present in certain Gram-negative bacterial infections, enabling differentiated and more sensitive detection of specific pathogens versus general LPS presence
Data Source
AI summary
Provided herein are compositions of trehalose phospholipids and uses thereof, e.g., compounds and compositions comprising 6,6′-diphosphatidyltrehalose (diPT) and analogs thereof with modifications of the diPT chemical scaffold, that bind and agonize Mincle, and the use thereof as adjuvants.